It's time to end insurance restrictions on life-saving hepatitis C treatments.
National Viral Hepatitis Roundtable, 1424 K St, Washington, DC 20005. E-mail: rclary@nvhr.org.
Ryan
R
Clary
D000998:Antiviral Agents / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006297:Health Services Accessibility / Q000191:economics* / Q000592:standards; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D007342:Insurance Benefits; D007348:Insurance, Health / Q000191:economics* / Q000592:standards; D008484:Medicaid / Q000191:economics / Q000592:standards; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents